Cosmos Holdings Inc. - COSM STOCK NEWS

Cosmos Holdings (NASDAQ:COSM) announced a name change to Cosmos Health, aiming to better represent its transformation into a global healthcare group focused on improving lives. This rebranding aligns with the company's strategy to enhance its R&D partnerships, including CloudPharm, and a proposed acquisition of a GMP medical manufacturing facility. Cosmos Health emphasizes an innovative approach in developing pharmaceutical and nutraceutical products, leveraging advanced technologies. The formal name change will be completed after the upcoming annual shareholders meeting.

Cosmos Holdings (NASDAQ:COSM) has appointed Dr. Manfred Ziegler to its Advisory Board, enhancing its leadership team. Dr. Ziegler, with over 30 years of experience in finance and operations, previously served as CEO of CC Pharma and played a crucial role in its acquisition by Aphria in 2019. His expertise in mergers and acquisitions is expected to support Cosmos's growth strategy through international expansion and innovative product development. CEO Greg Siokas expressed optimism about Dr. Ziegler's contributions, recognizing his strong track record.

Cosmos Holdings (NASDAQ:COSM) announced a binding letter of intent to acquire Pharmaceutical Laboratories CANA S.A., a Greek pharmaceutical company. Founded in 1928, Cana is known for its manufacturing and distribution of diverse health products and has partnerships with major global companies such as AstraZeneca and Merck. This acquisition aims to enhance Cosmos's vertical integration and expand its product portfolio. The move is expected to strengthen its competitive position in the pharmaceutical market, leveraging Cana's established customer base and operational capabilities.

Cosmos Holdings (Nasdaq:COSM) announced its subsidiary, Decahedron Ltd., has gained full membership in the PAGB, a leading UK consumer healthcare association. This membership enhances visibility for Sky Premium Life products on PAGB's OTC Directory, which attracts over 50,000 views monthly from healthcare professionals. The partnership is expected to improve access for pharmacies and boost consumer confidence in the products, which are now recognized as regulated items. This strategic move aims to expand Cosmos's market reach within the European Economic Area.

Cosmos Holdings (Nasdaq:COSM) announced the addition of Dr. Panagiotis Zoumpoulakis to its Advisory Board. With over 20 years in research, particularly in nutraceuticals, Dr. Zoumpoulakis holds a Ph.D. and an MBA. He is currently an Associate Professor at the University of West Attica and has published over 130 scientific works. His appointment comes after a strategic partnership with Cloudpharm P.C. to explore microbiome-based treatments for obesity. CEO Greg Siokas expressed confidence that Dr. Zoumpoulakis' expertise will be crucial for future projects.

Cosmos Holdings (Nasdaq:COSM) has announced an agreement to acquire LIFE NLB Ltd.'s product portfolio, which includes Bone-Vio® and Bone-X, aimed at enhancing bone health by targeting the gastrointestinal microbiome. This acquisition is positioned to establish Cosmos in the expanding osteoporosis drug market, valued at USD 13.36 billion and projected to grow at a CAGR of 6.83% to USD 20.17 billion by 2026. The Bone-Vio® product's clinical trial results are expected in 2023, highlighting its potential effectiveness in addressing osteoporosis.

Cosmos Holdings (NASDAQ:COSM) has formed a strategic partnership with Cloudpharm P.C., focused on developing innovative products targeting the human gastrointestinal microbiome. This collaboration aims to manage obesity by combining computational tools and natural products, with clinical trials expected to conclude in late 2023. The global weight management market, valued at USD $132.7 billion in 2021, is projected to grow at a CAGR of 9.7% over the next nine years. The partnership seeks to create high-quality nutraceuticals to address obesity and related health issues.

Cosmos Holdings (NASDAQ: COSM) announces the commercial launch of its Sky Premium Life nutraceutical products on Amazon in the U.S., following successful market entries in Canada, the U.K., and Singapore. The company plans to introduce 15 SKUs in the third quarter of 2022 and aims for all 85 SKUs available by year-end. The U.S. nutraceutical market is projected to grow at a 7.1% CAGR, reaching $138.0 billion by 2027, driven by health-conscious consumer trends. CEO Greg Siokas emphasizes the significant demand for high-quality supplements.

Cosmos Holdings (NASDAQ: COSM) reported strong financial results for Q1 2022, with revenue increasing by 12.5% to $13.1 million and gross profit soaring 88.9% to $1.89 million. The company achieved a net income of $0.2 million and EBITDA of $1.2 million. Growth was driven by a 49.2% increase in sales of its proprietary nutritional supplements. Operating expenses were reduced by nearly 40%, enhancing profitability. The company aims to expand its nutraceutical portfolio and geographic reach, launching products in Amazon Singapore and Canada.